[HTML][HTML] Mitochondria and doxorubicin-induced cardiomyopathy: a complex interplay
L Schirone, L D'Ambrosio, M Forte, R Genovese… - Cells, 2022 - mdpi.com
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
Mitochondria and doxorubicin-induced cardiomyopathy. A complex interplay
L Schirone, L D'Ambrosio, M Forte, R Genovese… - CELLS, 2022 - iris.uniroma1.it
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay.
L Schirone, L D'Ambrosio, M Forte… - Cells (2073 …, 2022 - search.ebscohost.com
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay
L Schirone, L D'Ambrosio, M Forte, R Genovese… - Cells, 2022 - pubmed.ncbi.nlm.nih.gov
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay
L Schirone, L D'Ambrosio, M Forte, R Genovese… - 2022 - agris.fao.org
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay
L Schirone, L D'Ambrosio, M Forte, R Genovese… - Cells, 2022 - search.proquest.com
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
[HTML][HTML] Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay
L Schirone, L D'Ambrosio, M Forte, R Genovese… - Cells, 2022 - ncbi.nlm.nih.gov
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay.
L Schirone, L D'Ambrosio, M Forte, R Genovese… - Cells, 2022 - europepmc.org
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first non-cancer …
[PDF][PDF] Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay. Cells 2022, 11, 2000
L Schirone, L D'Ambrosio, M Forte, R Genovese… - 2022 - iris.uniroma1.it
Cardiotoxicity has emerged as a major side effect of doxorubicin (DOX) treatment, affecting
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first noncancer …
nearly 30% of patients within 5 years after chemotherapy. Heart failure is the first noncancer …